With the recently solved crystal structure of the murine mu opioid receptor, the elucidation of the structure function relationships of the human mu receptor becomes feasible. In this study, we analyzed the available structural information along with ligand binding and G protein activation of human mu receptor. Affinity determinations were performed in a HEK293 cell line stably transfected with the human mu opioid receptor for 6 different agonists (morphine, DMAGO, and herkinom) and antagonists (naloxone, beta-Funaltrexamine, and Norbinaltorphimine). G protein activation was investigated in membrane preparations containing human mu receptors treated with the agonist, partial agonist, or antagonist compounds. 4DKL.pdb was utilized for structural analysis and docking calculations for 28 mu receptor ligands. The predicted affinities from docking were compared with those experimentally determined. While all known ligands bind to the receptor through the same binding site that is large enough to accommodate molecules of various sizes, interaction with D147 (D149 in human mu receptor) is essential for binding. No distinguishable interaction pattern in the binding site for agonist, partial agonist, or antagonist to predict pharmacological activities was found. The failure to reconcile the predicted affinities from docking with experimental values indicates that the receptor might undergo significant conformational changes from one state to the other states upon different ligand binding. A simplified model to understand the complicated system is proposed and further study on these multiple conformations using high resolution structural approaches is suggested. (C) 2013 Elsevier B.V. All rights reserved.
基金:
NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08-GM-093115-01]; Intramural Research Program of the NIAAA, NIH; department of anesthesiology and Critical Care at University of Pennsylvania; Foundation for Anesthesia Education and Research; Department of Anesthesiology at Beijing Tongren Hospital; National Institute of Mental Health's Psychoactive Drug Screening ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [HHSN-271-2008-00025-C (NIMH PDSP)]; GROFF; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM093115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000003] Funding Source: NIH RePORTER
第一作者机构:[1]Capital Med Univ, Beijing Tongren Hosp, Dept Anesthesiol, Beijing, Peoples R China[2]Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA
通讯作者:
通讯机构:[2]Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA[*1]Univ Penn, Sch Med, Dept Anesthesiol & Crit Care, 336 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA
推荐引用方式(GB/T 7714):
Cui Xu,Yeliseev Alexei,Liu Renyu.Ligand interaction, binding site and G protein activation of the mu opioid receptor[J].EUROPEAN JOURNAL OF PHARMACOLOGY.2013,702(1-3):309-315.doi:10.1016/j.ejphar.2013.01.060.
APA:
Cui, Xu,Yeliseev, Alexei&Liu, Renyu.(2013).Ligand interaction, binding site and G protein activation of the mu opioid receptor.EUROPEAN JOURNAL OF PHARMACOLOGY,702,(1-3)
MLA:
Cui, Xu,et al."Ligand interaction, binding site and G protein activation of the mu opioid receptor".EUROPEAN JOURNAL OF PHARMACOLOGY 702..1-3(2013):309-315